Screening for cervical cancer: Choices & dilemmas

被引：33
作者：
Rajaram, Shalini [1 ,3 ]
Gupta, Bindiya [2 ]
机构：
[1] All India Inst Med Sci, Dept Obstet & Gynecol, Rishikesh, Uttarakhand, India
[2] Univ Coll Med Sci & Guru Teg Bahadur Hosp, Delhi, India
[3] AIIMS Rishikesh, Dept Obstet & Gynecol, Veerbhadra Rd, Rishikesh 249203, Uttaranchal, India
来源：
INDIAN JOURNAL OF MEDICAL RESEARCH | 2021年 / 154卷 / 02期
关键词：
Biomarker; cervical cancer screening; cervical cytology; DNA methylation; HPV DNA testing; p16/Ki 67 dual staining; VIA; HUMAN-PAPILLOMAVIRUS DNA; HPV-POSITIVE WOMEN; LIQUID-BASED CYTOLOGY; EXTENDED FOLLOW-UP; CLINICAL-PERFORMANCE; VISUAL INSPECTION; ACETIC-ACID; INTRAEPITHELIAL NEOPLASIA; BASE-LINE; RISK;
D O I：
10.4103/ijmr.IJMR_857_20
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Cervical cancer is the fourth most common cancer in women in the world. To eliminate cervical cancer by 2030, the World Health Organization has given the target of 70 per cent coverage of twice lifetime screening. A multitude of screening methods are available, including cytology, human papillomavirus (HPV) DNA testing and visual inspection tests. Precision tests, including molecular and protein biomarkers such as DNA methylation, p16 immunostaining, and HPV mRNA testing help to enhance specificity of the screening. Worldwide HPV DNA testing with or without cytology is used as a screening method of choice, while in resource-poor settings, visual inspection tests are recommended. The major hurdle is a uniform and systematic implementation with a recall method in the population. Besides, controversies still exist regarding strategies to manage HPV-positive women and developing guidelines to screen the vaccinated population.
引用
收藏
页码：210 / 220
页数：11
相关论文
共 79 条
  • [11] Global elimination of cervical cancer as a public health problem
    Brisson, Marc
    Drolet, Melanie
    [J]. LANCET ONCOLOGY, 2019, 20 (03) : 319 - 321
  • [12] Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries
    Canfell, Karen
    Kim, Jane J.
    Brisson, Marc
    Keane, Adam
    Simms, Kate T.
    Caruana, Michael
    Burger, Emily A.
    Martin, Dave
    Nguyen, Diep T. N.
    Benard, Elodie
    Sy, Stephen
    Regan, Catherine
    Drolet, Melanie
    Gingras, Guillaume
    Laprise, Jean-Francois
    Torode, Julie
    Smith, Megan A.
    Fidarova, Elena
    Trapani, Dario
    Bray, Freddie
    Ilbawi, Andre
    Broutet, Nathalie
    Hutubessy, Raymond
    [J]. LANCET, 2020, 395 (10224) : 591 - 603
  • [13] Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia
    Canfell, Karen
    Saville, Marion
    Caruana, Michael
    Gebski, Val
    Darlington-Brown, Jessica
    Brotherton, Julia
    Heley, Stella
    Castle, Philip E.
    [J]. BMJ OPEN, 2018, 8 (01):
  • [14] Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial
    Carozzi, Francesca
    Gillio-Tos, Anna
    Confortini, Massimo
    Del Mistro, Annarosa
    Sani, Cristina
    De Marco, Laura
    Girlando, Salvatore
    Rosso, Stefano
    Naldoni, Carlo
    Dalla Palma, Paolo
    Zorzi, Manuel
    Giorgi-Rossi, Paolo
    Segnan, Nereo
    Cuzick, Jack
    Ronco, Guglielmo
    [J]. LANCET ONCOLOGY, 2013, 14 (02) : 168 - 176
  • [15] Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial
    Cook, Darrel A.
    Smith, Laurie W.
    Law, Jennifer H.
    Mei, Wendy
    Gondara, Lovedeep
    van Niekerk, Dirk J.
    Ceballos, Kathy M.
    Jang, Dan
    Chernesky, Max
    Franco, Eduardo L.
    Ogilvie, Gina S.
    Coldman, Andrew J.
    Krajden, Mel
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2018, 108 : 32 - 37
  • [16] Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial
    Cook, Darrel A.
    Smith, Laurie W.
    Law, Jennifer
    Mei, Wendy
    van Niekerk, Dirk J.
    Ceballos, Kathy
    Gondara, Lovedeep
    Franco, Eduardo L.
    Coldman, Andrew J.
    Ogilvie, Gina S.
    Jang, Dan
    Chernesky, Max
    Krajden, Mel
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2017, 87 : 23 - 29
  • [17] Clinical Performance of Roche Cobas 4800 HPV Test
    Cui, Miao
    Chan, Nicholas
    Liu, Momo
    Thai, Khanh
    Malaczynska, Joanna
    Singh, Ila
    Zhang, David
    Ye, Fei
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (06) : 2210 - 2211
  • [18] Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs
    Cuschieri, Kate
    Ronco, Guglielmo
    Lorincz, Attila
    Smith, Laurie
    Ogilvie, Gina
    Mirabello, Lisa
    Carozzi, Francesca
    Cubie, Heather
    Wentzensen, Nicolas
    Snijders, Peter
    Arbyn, Marc
    Monsonego, Joe
    Franceschi, Silvia
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (04) : 735 - 745
  • [19] Clinical, colposcopic and pathological characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2
    del Pino, Marta
    Rodriguez-Carunchio, Leonardo
    Alonso, Immaculada
    Torne, Aureli
    Rodriguez, Agata
    Fuste, Pere
    Castillo, Paola
    Nonell, Roser
    Abu-Lhiga, Nadia
    Ordi, Jaume
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 122 (03) : 515 - 520
  • [20] Denny L, 2000, CANCER-AM CANCER SOC, V89, P826, DOI 10.1002/1097-0142(20000815)89:4<826::AID-CNCR15>3.0.CO
12345678